Future of anti-VEGF: biosimilars and biobetters

International Journal of Retina and Vitreous

Suvansh Nirula¹  Monika Kapur²  Mayuresh P. Naik³ 

[1] Department of Ophthalmology, H.I.M.S.R & H.A.H.C Hospital, near GK-2, 110062, Alaknanda, New Delhi, India;Department of Ophthalmology, H.I.M.S.R. & H.A.H.C. Hospital, Hamdard University, Room No.3 of Eye OPD, First Floor of New OPD Building, H.A.H.C. Hospital, near GK-2, Alaknanda, 110062, New Delhi, Delhi, India;Oxford Eye Hospital, John Radcliffe Hospital, Oxford University Hospitals NHS Trust, Headley way, OX3 9DU, Headington, Oxford, UK;

关键词: Biosimilars;    Biobetters;    Anti-VEFG;   

DOI  :  10.1186/s40942-021-00343-3

来源: Springer

【 摘 要 】

The advent of Anti- VEGFs like Lucentis (Ranibizumab), Eylea (Aflibercept) and off-label Avastin (Bevacizumab) have radically improved visual outcomes in patients of neovascular Age Related Macular Degeneration (nARMD), Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO). It is a matter of great concern that the US patents for Ranibizumab and Aflibercept expired in 2020 with European patents to expire in 2022 and 2025, respectively. With the expiry of these biologics, Biosimilars can prove to be saviours in the posterior segment pharmacotherapy owing to their cost effectiveness and availability of various options. Numerous biosimilars are expected to gain approval for clinical use from the US-FDA and EMA soon. Biobetters are better than the original biologic in one or more parameters but require more research and development resources. With the emergence of better manufacturing and purification processes it is imperative that the biologics and biosimilars become better. The Ophthalmologists need to have in depth knowledge about these Biosimilars and Biobetters before these molecules take over the mainstream market.

【 授权许可】

CC BY